Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Transl Res. 2018 Jan 10;194:56–67. doi: 10.1016/j.trsl.2018.01.001

Table 2.

NIA-AA Criteria for preclinical AD research (adapted from (2))

Stages A β (PET or CSF) Neuronal injury markers (FDG, tau, MRI) Subtle cognitive change
Stage 1 (Asymptomatic cerebral amyloidosis) Positive Negative Negative
Stage 2 (Amyloid positivity + synaptic dysfunction and/or neurodegeneration) Positive Positive Negative
Stage 3 (Amyloid positivity + neurodegeneration + subtle cognitive decline) Positive Positive Positive